L-FABP ELISA
- Known as:
- L-FABP Enzyme-linked immunosorbent assay test
- Catalog number:
- kt-563
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Kamiya biomedical company
- Gene target:
- L-FABP ELISA
Related products to: L-FABP ELISA
Related articles to: L-FABP ELISA
- Hepatocellular carcinoma (HCC) is a cancer with high incidence and mortality rate. Although immune checkpoint inhibitors (ICIs) improved survival outcomes for HCC patients, limited objective response rate highlights the urgency of investigating determinants of immunotherapy. Here, we explore HCC resistance mechanisms following neoadjuvant αPD-1 immunotherapy by constructing a comprehensive multi-modal single-cell transcriptomic atlas consisting of 14 HCC patients treated with αPD-1 from our cohort (ClinicalTrials.gov ID: NCT06571396) and 60 external HCC cases with heterogeneous treatment backgrounds. Supervised by clinical outcomes of our cohort, we identify positive and negative regulators of immunotherapy within the tumor immune microenvironment (TIME), especially lipid-associated macrophages (LAM) with increased lipid metabolic state in non-responders and characterized by C1QA, FABP1, and APOA1 expression. We further show the presence, exogenous inducements and immunosuppressive functions of LAM, along with regulation strategies of its lipid-associated condition, including lycopene and chiglitazar. Furthermore, we construct interaction networks of immune regulators across responders and non-responders, showing distinct ligand-receptor landscapes with intervention targets. We reveal the TIME components including immunosuppressive LAMs that influence immunotherapy outcomes, thus providing evidence and insights for exploring immune landscape and therapeutic strategies for HCC immunotherapy. ClinicalTrials.gov ID: NCT06571396. - Source: PubMed
Publication date: 2026/07/31
Peng ShengxuanLiu ChangLong JunyuTian JinchengLi HanLu DonghaiCao QihangZhang DaolinHe QiaoJia JisenWang YuxuanDong ZhaoruZhao HaitaoZhao LeiWang DongxuLi Tao - Premature ovarian insufficiency (POI) is a leading cause of female infertility. Its mechanisms are poorly understood, and effective therapies are lacking. In this study, we aimed to identify novel druggable targets and repurposable drugs for POI through an integrated multiomics and computational pharmacology approach. We integrated large-scale proteomic data from two independent cohorts (deCODE, N = 35,559; UK Biobank, N = 54,219) using Mendelian randomization, Bayesian colocalization, and single-cell RNA sequencing. Seven high-confidence targets were identified: EPHA4, FSTL3, NUCB2, OXT, SERPINA12, TNFRSF6B, and FABP1. Among these genes, EPHA4, FSTL3, and NUCB2 were significantly dysregulated in cisplatin-induced mouse and human granulosa cell models (P < 0.05 to P < 0.001) and exhibited high diagnostic accuracy (AUC = 0.92-0.96), supporting their potential as both biomarkers and therapeutic targets. Molecular docking revealed strong binding affinities, notably for cycloheximide binding to EPHA4 (-7.8 kcal/mol), with molecular dynamics confirming stable interactions (root mean square deviation, RMSD < 2.0 Å), providing a structural basis for drug repurposing or lead optimization. The functional enrichment results suggested that fibrosis, inflammation, and metabolic dysregulation are involved in POI pathogenesis. Collectively, our findings establish a multiomics-to-therapy pipeline that not only prioritizes causal targets for POI but also provides translational opportunities, from biomarker-guided diagnosis to computationally driven drug repositioning, paving the way for mechanism-based interventions in ovarian aging. - Source: PubMed
Publication date: 2026/08/28
Liu ChaoWang RunzhiLiu XinnongLi YuanRen LiliZhao ZhiyuFan ZhongkaiXiao Jianying - The associations between objectively measured sleep patterns, the hallmarks of aging, and their shared proteomic signatures remain poorly understood. In this study, we utilized wrist-worn accelerometer data, plasma proteomic profiles, and health records from the UK Biobank to examine the associations between six defined sleep patterns and nine established hallmarks of aging. We further identified proteins jointly associated with both sleep patterns and aging hallmarks. Longer total sleep duration, greater deep sleep, and increased rapid eye movement (REM) sleep were associated with lower risk of most aging hallmarks. In contrast, higher wakefulness after sleep onset (WASO) and greater sleep irregularity were associated with higher risk, whereas light sleep showed no significant associations. The number of overlapping proteins varied substantially across sleep-hallmark associations, ranging from 1 to 558. These proteins were predominantly enriched in immune and inflammatory pathways. Several proteins, including IL1RN, FABP1, GDF15, and LEP, were consistently observed across multiple sleep patterns and aging hallmarks. These findings may help generate hypotheses about shared underlying biological processes between sleep and the aging process. - Source: PubMed
Liu RuiyiLuo JingsongZhang YangchangWang FurongXu JingCao WangnanSun Shengzhi - With the application of high-fat diets (HFDs) leading to increased prevalence of fatty liver in aquaculture, plant extracts such as olive () leaf extract (OLE) have attracted much attention due to their potential bioactive effects. In the present study, five experimental groups were established with HFD (15.5% crude lipid) supplemented with 0.0%, 0.5%, 1.0%, 1.5%, and 2.0% OLE, respectively, and each was fed to three replicate cages containing 20 juvenile (initial body weight: 11.57 ± 0.19 g) per cage. Fish fed HFD supplemented with 1.0% OLE showed significantly increased growth and survival and reduced lipid content in whole fish and triglyceride (TG) and cholesterol contents in serum compared to fish fed HFD ( < 0.05). Analysis of liver gene expression showed that reduced lipid content might be associated with reduced expression of genes associated with lipid synthesis (sterol regulatory element binding protein 1 [], fatty acid synthase [], acetyl-CoA carboxylase [], and diacylgycerol acyltransferase 1 []), and increased expression of genes associated with fatty acid oxidation (peroxisome proliferator-activated receptor α [], hormone-sensitive lipase [], and carnitine palmitoyl transferase-1 []) and lipid transport (CD36 molecule [] and fatty acid binding protein 1 []). Inclusion of OLE not only significantly lowered serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities but also increased activities of serum alkaline phosphatase (AKP) and superoxide dismutase (SOD) and total antioxidant capacity (TAOC), while serum malondialdehyde (MDA) decreased in fish fed HFD with 0.5%-1.0% OLE compared to fish fed HFD ( < 0.05). Additionally, 0.5%-1.0% dietary OLE significantly enhanced the integrity of intestinal morphology, reduced intestinal lipase activity and expression of inflammatory factors (interleukin-1 [] and ), and increased the diversity of intestinal microbiota ( < 0.05). The abundance of beneficial bacterial taxa () was increased, while harmful bacterial taxa () decreased in fed diets with OLE compared to fish fed HFD. The data suggested that dietary OLE (particularly 1.0%) alleviated the negative effects of HFD in , which has highlighted the positive impacts of dietary OLE in fish and provided a new development opportunity for the olive industry through utilization of production waste. - Source: PubMed
Publication date: 2026/08/21
Xie JiayingShen JiajianTocher Douglas RLi YuanyouHao YansenLin ZelingZhan HanLin FanWang ShuqiChen Cuiying - The biological efficacy of dietary lysophospholipids (LPLs) in broiler diets may be significantly modulated by their technical delivery methods. This study evaluated the effects of direct solid addition and liquid applications (oil-water pre-emulsification or pure oil pre-mixing) of LPLs on growth performance, nutrient digestibility, intestinal morphology, and gene expression in broilers fed energy-reduced diets. A total of 480 one-day-old male Ross 308 broilers were assigned to five treatments, with eight replicate pens of 12 birds. The treatments were a basal diet (T1), an energy-reduced diet (T2; 100 kcal/kg less metabolizable energy [ME]), and T2 supplemented with LPLs. The supplemented treatments received solid LPLs at 250 g/t (T3), oil-water pre-emulsified liquid LPLs at 500 g/t (T4), or oil-premixed liquid LPLs at 500 g/t (T5).Reducing dietary energy significantly deteriorated the overall feed conversion ratio (FCR) (P < 0.05). Broilers in liquid LPL groups exhibited higher final body weights and lower d21-42 FCR compared to both T2 and T3 groups (P < 0.05), with no differences between T4 and T5. All LPL treatments improved the digestibility of crude fat, gross energy and dry matter on days 21 and 42 (P < 0.05), while liquid methods further maximized dry matter digestibility at day 42 (P < 0.05). Morphologically, LPL supplementation restored the jejunal villus height to crypt depth ratio compromised by the low-energy diet (P < 0.05). Compared with solid addition, liquid LPLs increased the relative mRNA abundance of L-type amino acid transporter 1 (LAT1), cationic amino acid transporter 1 (CAT1), fatty acid-binding protein 1 (FABP1). In conclusion, liquid LPL applications are superior to traditional solid addition in enhancing broiler finisher growth performance, nutrient digestibility, and transporter gene expression in reduced-energy diet. Notably, direct pre-mixing of LPLs in dietary oil is as highly effective as external oil-water pre-emulsification, offering an optimized strategy for reduced-energy dietary utilization. - Source: PubMed
Publication date: 2026/07/30
Zhang SongJiang XunpengWang SonglinWei YeLi Jian